<div id="readability-page-1"><p>First American Trust FSB decreased its stake in  Novo Nordisk A/S (NYSE:NVO - Free Report) by 50.9% in the first quarter, according to the company in its most recent 13F filing with the SEC. The firm owned 21,403 shares of the company's stock after selling 22,145 shares during the quarter. First American Trust FSB's holdings in Novo Nordisk A/S were worth $1,486,000 at the end of the most recent reporting period.</p><div><p><span></span><span>Get <strong>Novo Nordisk A/S</strong> alerts:</span></p></div><ul><li>Trump GLP-1 Pilot Program Could Boost Novo Nordisk &amp; Eli Lilly</li></ul><p>Other institutional investors and hedge funds have also recently modified their holdings of the company. Strategic Investment Solutions Inc. IL boosted its holdings in shares of  Novo Nordisk A/S by 2,727.3% in the 4th quarter. Strategic Investment Solutions Inc. IL now owns 311 shares of the company's stock worth $27,000 after purchasing an additional 300 shares during the period.  Park Square Financial Group LLC bought a new stake in shares of  Novo Nordisk A/S during the 4th quarter worth approximately $29,000.  Transce3nd LLC bought a new stake in shares of  Novo Nordisk A/S during the 4th quarter worth approximately $33,000.  North Capital Inc. bought a new stake in shares of  Novo Nordisk A/S during the 1st quarter worth approximately $27,000.  Finally, Copeland Capital Management LLC lifted its stake in shares of  Novo Nordisk A/S by 184.8% during the 1st quarter. Copeland Capital Management LLC now owns 393 shares of the company's stock worth $27,000 after acquiring an additional 255 shares during the last quarter. Hedge funds and other institutional investors own  11.54% of the company's stock. </p><h2>Analyst Upgrades and Downgrades</h2><p>NVO has been the subject of a number of research analyst reports. BMO Capital Markets  reissued a &#34;market perform&#34; rating and set a $64.00 price target (down from $105.00) on shares of Novo Nordisk A/S in a research note on Thursday, April 17th. Barclays  reissued an &#34;equal weight&#34; rating on shares of Novo Nordisk A/S in a research note on Wednesday, July 30th. Guggenheim lowered Novo Nordisk A/S from a &#34;strong-buy&#34; rating to a &#34;hold&#34; rating in a research note on Thursday, April 17th. BNP Paribas initiated coverage on Novo Nordisk A/S in a research note on Tuesday, April 15th. They set an &#34;underperform&#34; rating for the company. Finally, HSBC lowered Novo Nordisk A/S from a &#34;buy&#34; rating to a &#34;hold&#34; rating and set a $57.00 price target for the company. in a research note on Thursday, July 31st. Two research analysts have rated the stock with a sell rating, ten have issued  a hold rating and two have issued  a buy rating to the company. According to MarketBeat.com, Novo Nordisk A/S currently has an average rating of &#34;Hold&#34; and a consensus price target of $93.67.</p><ul><li>MarketBeat Week in Review – 08/04 - 08/08</li></ul><p><b>View Our Latest Report on Novo Nordisk A/S</b></p><h2>Novo Nordisk A/S Trading Up 4.7%</h2><p>Shares of NYSE NVO opened at $51.06 on Friday. The company has a quick ratio of 0.56, a current ratio of 0.78 and a debt-to-equity ratio of 0.52. The business has a fifty day simple moving average of $67.14 and a two-hundred day simple moving average of $71.54. The firm has a market cap of $227.98 billion, a PE ratio of 14.03, a price-to-earnings-growth ratio of 1.54 and a beta of 0.63. Novo Nordisk A/S has a twelve month low of $45.05 and a twelve month high of $139.74. </p><ul><li>Is Eli Lilly’s 14% Post-Earnings Slide a Buy-the-Dip Opportunity?</li></ul><p>Novo Nordisk A/S (NYSE:NVO - Get Free Report) last issued its earnings results on Wednesday, August 6th. The company reported $0.97 earnings per share for the quarter, beating analysts' consensus estimates of $0.93 by $0.04. The business had revenue of $11.69 billion during the quarter, compared to analyst estimates of $77.51 billion. Novo Nordisk A/S had a return on equity of 78.64% and a net margin of 35.60%.  Analysts expect that  Novo Nordisk A/S will post 3.84 earnings per share for the current fiscal year. </p><h2>Novo Nordisk A/S Cuts Dividend</h2><p>The business also recently declared a semi-annual dividend, which will be paid on Tuesday, August 26th. Stockholders of record on Monday, August 18th will be given a $0.4119 dividend. This represents a dividend yield of 240.0%. The ex-dividend date of this dividend is Monday, August 18th. Novo Nordisk A/S's payout ratio is presently 45.05%. </p><h2>Novo Nordisk A/S Profile</h2> (Free Report)<p>Novo Nordisk A/S, together with its subsidiaries, engages in the research and development, manufacture, and distribution of pharmaceutical products in Europe, the Middle East, Africa, Mainland China, Hong Kong, Taiwan, North America, and internationally. It operates in two segments, Diabetes and Obesity Care, and Rare Disease.</p><h2>Featured Stories</h2><ul><li>Five stocks we like better than Novo Nordisk A/S</li><li>Investing In Preferred Stock vs. Common Stock</li><li>Rocket Lab Reports Q2 Results: Is the Bull Thesis Still Intact?</li><li>ESG Stocks, What Investors Should Know</li><li>Trump GLP-1 Pilot Program Could Boost Novo Nordisk &amp; Eli Lilly</li><li>High Flyers: 3 Natural Gas Stocks for March 2022</li><li>Now Is a Great Time to Buy Cheniere Energy: New High Expected</li></ul><p><strong>Want to see what other hedge funds are holding NVO?</strong> Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Novo Nordisk A/S (NYSE:NVO - Free Report).</p><p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/SECFilingChart.ashx/query-UHJlZml4PU5ZU0UmU3ltYm9sPU5WTw?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" width="650" height="350" original-src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/SECFilingChart.ashx/query-UHJlZml4PU5ZU0UmU3ltYm9sPU5WTw"/></p><p><em>This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.</em></p><h2>Should You Invest $1,000 in Novo Nordisk A/S Right Now?</h2><p>Before you consider Novo Nordisk A/S, you'll want to hear this.</p><p>MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Novo Nordisk A/S wasn't on the list.</p><p>While Novo Nordisk A/S currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.</p><p>View The Five Stocks Here</p>                  </div>

<p>First American Trust FSB reduced its stake in Novo Nordisk A/S (NYSE:NVO) by 50.9% in Q1, owning 21,403 shares after selling 22,145 shares. The holdings were valued at $1,486,000. Other institutional investors also adjusted their positions, with Strategic Investment Solutions increasing its stake significantly. Analysts have mixed ratings on Novo Nordisk, with a consensus rating of "Hold" and a price target of $93.67. The company reported earnings of $0.97 per share, beating estimates, and declared a semi-annual dividend of $0.4119, yielding 240.0%.</p>

First American Trust FSB Reduces Stock Holdings in Novo Nordisk A/S (NYSE:NVO)